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Abstract
Purpose: The objective of this study is to validate a procedure based on a statistical method to assess the agreement and the
correlation between measured and calculated dose in the process of quality assurance (QA) for intensity-modulated radiation
therapy (IMRT).Methods: Fifty-six fields for head and neck cancer treatment from 10 patients were analyzed. For each patient a
treatment plan was generated using Eclipse TPS®. To compare the calculated dose with the measured dose a CT-scan of solid
water slabs (30 × 30 × 15 cm3) was used. Absolute dose was measured by a pinpoint ionization chamber and 2D dose distributions
using electronic portal imaging device dosimetry. Six criteria levels were applied for each field case (3%, 3 mm), (4%, 3 mm),
(5%, 3 mm), (4%, 4 mm), (5%, 4 mm) and (5%, 5 mm). The normality of the data and the variance homogeneity were tested using
Shapiro-Wilk’s test and Levene’s test, respectively. The Wilcoxon signed-rank paired test was used to calculate p-values. The
Bland-Altman method was used to calculate the limit of agreement between calculated and measured doses and to draw a scatter
plot. The correlation between calculated and measured doses was assessed using Spearman’s rank test. Results: The statistical tests
indicate that the data were not normally distributed, p < 0.001, and had a homogenous variance, p = 0.85. The upper and lower
limits of agreement for absolute dose measurements were 6.44% and -6.40%, respectively. The Wilcoxon test indicated a
significant difference between calculated and dose measured with the ionization chamber, p = 0.01. Spearman’s test indicated a
strong correlation between calculated and absolute measured dose, with correlation coefficient ρ = 0.99. Therefore, there is a lack
of correlation between dose difference for absolute dose measurements and gamma passing rates for 2D dose measurements.
Conclusion: The statistical tests showed that the commonly accepted criteria using gamma evaluation are not able to predict the
dose difference for a global treatment plan or per beam. The current QA method provides inadequate protection of the patient.
The method described here provides an overall analysis for dosimetric data from calculation and measurement, and can be
quickly integrated into QA systems for IMRT.
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Introduction
The objective of radiation therapy is to obtain the highest
probability of tumor control or cure with the least amount of
morbidity and toxicity to normal tissues, namely the organs at
risk (OAR). Currently, numerous different irradiation
techniques are available and can be used to irradiate tumors,
such as three dimensional radiation therapy (3DRT), intensity
-modulated radiation therapy (IMRT), volumetric-modulated
arc therapy (VMAT) and tomotherapy, etc. IMRT/VMAT
have the benefit of protecting the OAR while giving higher
doses to the target volumes. These techniques use a multi leaf
collimator (MLC), where the leaves are individually moving
during the irradiation producing a kind of crawling gap
during the beam shot. This requires more monitor units
compared to 3DRT. This highly complex design needs a
systematic and specific quality assurance (QA) method to
compare the calculated dose given by the TPS, with the
measured dose, that will actually be delivered, for each field.
Currently, there are a wide range of recommendations for
QA in IMRT measurements, such as AAPM (American
Association of Physicists in Medicine) and ESTRO (European
Society for Radiotherapy & Oncology) guidelines, etc.1,2,3,4
One possibility for QA can be performed by applying the
calculated treatment planned for each field of a specific
patient to a virtual solid water phantom with simple
geometry. Then the calculated doses or the beam fluence are
compared with the measured dose or fluence at the linear
accelerator. The QA method may consist of two types of
comparisons: i) point dose measurements (absolute dose)
using a small ionization chamber; ii) comparison with planer
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dose represented by the fluence distributions in 2D, using a
2D dosimeter.
Point dose measurements are done for 2-3 points and the
tolerance is 2-3% between measured and calculated dose. To
compare the fluence distribution delivered by the LINAC
with the calculated dose, a global evaluation can be done
using the gamma index (γ).5,6 Quality radiation treatment
relies on the agreement between calculated and measured
dose, which depends on the precision of the dose calculation
algorithm, the calibration of the ionization chamber,
validation thresholds, either global or local γ evaluation,
percentage tolerances for dose difference (DD) and distance
to agreement (DTA) value, etc. Advanced ‘type b’ algorithms
such as the Anisotropic Analytical Algorithm and Collapsed
Cone Convolution are more accurate and show less dose
difference compared with former algorithms.7 These complex
and time consuming 2D protocols are not completely accurate
and have drawbacks that should be highlighted and addressed
to improve them.
Currently, the residual 5% non-conformity in the γ
evaluation accounts for 50 mL per liter of irradiated tissue, in
which we control neither the exact anatomical position nor
the tolerance consequences for the clinical outcome.
Moreover, anatomical information is completely excluded
from these QA methodologies.
However, good treatment QA requires high accuracy of both
the calculated and measured dose in the 3D anatomical space
of the patient. Since it remains impossible to generate a real
anatomical assessment of the treatment by the treatment
beams without the patient, presently the beam by beam
validation procedure depends on the gamma criteria. In this
study we explore several gamma criteria including dose
difference and distance to agreement in order to ascertain the
best relevant criteria for IMRT-QA.
Methods and Materials
The implementation and validation of the statistical methods
consisted of 3 successive steps including the generation of
treatment plans, dosimetry measurements using a
homogenous phantom and then the statistical analysis.
Treatment plans
This study is based on 56 fields which were used to treat 10
patients with head and neck cancer. The computed
tomography (CT) images of each patient were loaded into the
Eclipse® Treatment Planning System TPS (Varian, version
8.9). Clinicians delineated the anatomic borders of target
structures and OAR. Then treatment plans were generated
with 5 to 10 fields for each patient. Dose calculations were
performed, using the pencil beam convolution (PBC)
algorithm with heterogeneity correction by the modified
Batho method (PBC-MB). The patients were treated by IMRT
and 6MV photon beams (Clinac 600, Varian) using the
monitor units calculated in these plans.
Phantom measurements
We consistently made a comparison of the doses calculated
with Eclipse® TPS and the measured doses at the accelerator
in the same conditions. For this a QA method for IMRT was
used consisting of measuring point by point absolute doses, as
well as studying the 2D dose distribution (fluence map). To
compare the calculated dose with the measured dose a
CT-Scan of solid water slabs (30 × 30 × 15 cm3) was done.
Figure 1 shows the solid water phantom and its CT-Scan
which was used to compare the calculated doses with
measured ones. All parameters of the treatment plan were
applied, except the gantry angle that was always set at 0
degree. The measurements were made on a Clinac600®
accelerator.
FIG. 1: Solid water phantom (left) and its CT Scan (right panel). This
phantom has been used to compare the calculated and measured
doses.
Absolute dose
A Pinpoint chamber, 0.0125 cm3 was used to measure the
absolute dose for four points in every field. These points were
selected in the flat domain of the dose profile calculated with
the TPS. The difference between calculated dose (Dc) and
measured dose (Dm) was calculated as follows:
DD% = (Dm - Dc) × 100 / Dc (1)
To validate a specific field the tolerance threshold was 3
points out of 4 having 3% or less difference.
Gamma passing rates
To compare the fluence map obtained from the TPS with the
dose fluence delivered by the accelerator, electronic portal
imaging device (Epid) dosimetry was used. The consistency
of measurements with calculations was assessed using the γ
index. Six criteria levels (DD, DTA) were applied for each
field (3%, 3 mm), (4%, 3 mm), (5%, 3 mm), (4%, 4 mm), (5%,
4 mm) and (5%, 5 mm). In all cases, gamma analysis was done
with relative and absolute evaluations.
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Statistical analysis
We used the Shapiro-Wilks test to assess the normality of
data and Levene’s test to assess whether the assumption of
homogeneity of variance was fulfilled. A Wilcoxon
signed-rank test was used to calculate the p-value. A bilateral
statistical test was realized with an error α = 5%,
corresponding to a 95% confidence interval. The dose
difference was considered significant if p < 0.05. To measure
the strength of the relationship between the calculated and
measured dose, Spearman’s rank non-parametric test used to
calculate correlation coefficient (ρ –values); then correlation
maps were generated. All statistical tests used in this study
were performed with the R programming language.8,9 The
upper limit of agreement (ULA) and lower limit of agreement
(LLA) were calculated using the following equations,10,11,12:
ULA = |average| + 2 × SD (2)
LLA = |average| - 2 × SD (3)
For the γ analyses, where perfect agreement produced a
passing rate of 100%, the confidence limit was defined as:
ULA = (100 - average) + 2 × SD (4)
LLA = (100 - average) - 2 × SD (5)
where, average was the mean percentage of points passing the
γ criteria and SD the standard deviation.
Results
Absolute dose
The tolerance condition for 3 points out of 4 having 3% or less
of difference was respected for all fields and the average dose
difference was 0.02 ± 3.2%. The Shapiro-Wilks test showed a
significant deviation from normality for DD with p < 0.001.
Levene’s test indicated that the calculated and measured
doses did not have significantly different variances, showing
homogeneous variance, p = 0.85. Accordingly, the
non-parametric Wilcoxon test was used to calculate the
p-value showing a significant difference between calculated
and measured dose of p = 0.01.
Gamma passing rate
Table 1 summarizes the dosimetry and statistical results for 10
patients treated with 56 beams. It can be seen that ULA and
LLA were always below 2% for all tolerance criteria. Figure 2
shows calculated, measured dose and γ passing rates for
absolute and relative evaluations using (3%, 3 mm) and (4%, 4
mm) criteria for a left anterior oblique beam. It can be seen in
Figure 2 that the tolerance level, 95% of pixels having γ < 1, is
not met using an absolute evaluation with (3%, 3 mm), but
was validated when an absolute evaluation with (4%, 4 mm)
was used. Thus, this case shows a minor deviation. Figure 3
shows the γ passing rates using all the tolerance levels for one
patient treated with five beams including one posterior, one
anterior and three oblique beams.
TABLE 1: The dosimetry and statistical results for 10 patients treated
with 56 beams. SD shows the standard deviation. ULA and LLA were
the upper and lower level of agreement, respectively. The p-values
were calculated using the Wilcoxon signed rank test.
γ criteria evaluation average SD ULA LLA p-value
3%,
3mm
relative 99.8 0.005 0.21 0.18 1.3E-06absolute 98.5 0.01 1.53 1.46
4%,
3mm
relative 100 0.001 0.003 -0.003 1.8E-06absolute 99.2 0.01 0.82 0.77
5%,
3mm
relative 100 0.0008 0.001 -0.001 1.20E-05absolute 99.5 0.008 0.5 0.48
4%,
4mm
relative 100 0.0006 0.001 -0.001 0.0002absolute 99.8 0.005 0.2 0.18
5%,
4mm
relative 100 0 0 0 0.001absolute 99.9 0.003 0.10 0.09
5%,
5mm
relative 100 0 0 0 0.09absolute 100 0.001 0.002 -0.002
FIG. 2: 2D dose distribution for calculated dose and measured dose by Epid for the left anterior oblique beam showing γ passing rates for absolute
and relative evaluations using (3%, 3 mm) and (4%, 4 mm) criteria.
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FIG. 3: γ passing rates for one patient using relative and absolute
evaluations with all γ criteria.
Statistical correlation
Absolute dose
The data obtained from calculated and measured doses
showed a strong correlation with correlation coefficient ρ =
0.99. Figure 4 shows the Bland–Altman plot presenting the
calculated and measured point doses as a function of dose
difference. The solid line in Figure 4 represents the average,
0.02%, the two dashed lines represent ULA and LLA, given
by equations 2 and 3, at 6.44% and -6.40%. It can be seen
that for lower doses, the dose difference can reach 15%.
FIG. 4: Bland–Altman plot showing dose difference as a function of
average doses for calculated and measured absolute points. The solid
line represents the average of 0.02%, the two dashed lines represent
ULA and LLA (6.44% and -6.40%) as given by equations 2 and 3.
Absolute dose and gamma passing rates
The data demonstrate that there is a lack of correlation
between γ passing rates and DD for all criteria with
correlation coefficient ρ ranging from to 0.03 to 0.29. Figure 5
shows an example of correlation plots between DD and γ
passing rate, for all beams, using absolute and relative
evaluations with (3%, 3 mm).
FIG. 5: Correlation plot between γ passing rates and dose difference.
Correlation between absolute and relative gamma passing
rates
Figure 6 shows the correlation maps for γ passing rates
generated for all gamma criteria ranging from 0 to ±1. The ρ
-values are color coded and the results of ρ -values were
between [-1; +1]. The white, blue and red coloring on the
correlation map show respectively very weak correlation,
strong positive correlation and strong negative correlation.
The correlation coefficient ρ-values for both criteria (5%, 4
mm) and (5%, 5 mm) with relative evaluations were not
calculable. We observed a strong correlation between γ
passing rates using (3%, 3 mm) and γ passing rate using (4%, 4
mm) for relative and absolute evaluations, as shown in Figure
6, with dashed boxes. Therefore, using criteria (4%, 4 mm)
the tolerance of 95% of pixels having γ < 1 was met. This
means that γ criteria (4%, 4 mm) can be used in the case of
minor deviations to compare calculated and measured fluence
in 2D.
FIG. 6: Correlation map between gamma passing rates using all
gamma criteria for all beams, “abs” and “rel” mean absolute and
relative evaluations. The correlation values calculated with
Spearman’s rank test ranged from 0 to ± 1. The white, blue and red
coloring in the correlation map show respectively very weak
correlation, strong positive correlation and strong negative
correlation. The dashed boxes show a strong correlation between γ
criteria (3%, 3 mm) and γ (4%, 4 mm) for both relative and absolute
evaluations, justifying the use of (4%, 4 mm) for minor deviations.
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Discussion
Influence of dosimetry data on confidence limits
The statistical analysis of 188 points showed that 82.4% were
within the threshold of acceptable tolerance of ± 3%.
Spearman’s rank test showed an excellent correlation
between calculated and measured absolute doses with ρ =
0.99, as shown in Figure 7 where median values are 0.4 for
both calculated and measured doses. However, our data do
not have a normal distribution; in this case the multiplying
factor “2” in equations 2, 3, 4 and 5 was used to calculate ULA
and LLA. Using a factor 1.96 instead of 2 in these equations
would more precisely give the values of the 95% interval if
these distributions were truly normal. Both confidence limits
depend on assumptions such as normal distribution, sample
size, standard deviation and average difference. Moreover,
the difference between measured and calculated doses
depends also on the precision of dose calculation algorithm.
Hence, the validation of the treatment plan for each field is
based on the assessment of the dose calculation. Currently,
numerous different algorithms are available. The algorithms
were categorized into two groups ‘type a’ or ‘type b’ according
to the electron transport calculation. More recently, ‘type c’
algorithm is available, such as Acuros XB, Varian's Eclipse
TPS (Varian Medical Systems, Palo Alto, CA).7, 13 In this study
PBC-MB density correction have been used. PBC-MB is based
on ‘type a’ which does not take into account the changes in
lateral electron transport.14-18 However, Acuros XB is more
accurate and recommended for heterogeneity correction.19-21
FIG. 7: Boxplot for dose difference obtained from 56 fields indicating
the minimum, median as a black line (in the red part) and maximum
values, as well as the 25th and 75th percentiles. The median values
were 0.4 for calculated and measured doses. This representation is not
adapted to show the differences but the internal distribution of
values.
FIG. 8: 8.a. distributions of α and β generated for the Wilcoxon test, with α = 0.05, power = 0.95, effect size = 0.46 and sample size = 56 and figure
8.b. presents the sample size as a function of power, it can be seen n= 56 represents a power of 95% (GPower software).
In order to properly assess the correlation between calculated
and measured doses, the power of the statistical test (1- β) was
calculated with the sample size used in this study, n= 56.22,23
This power had been calculated according to the
requirements of the Wilcoxon test with α = 0.05, effect size =
0.46, leading to a power = 0.95. Figure 8.a shows the
distribution of α and β generated by the Wilcoxon test under
the above conditions and Figure 8.b. shows the sample size as
a function of power generated by the Wilcoxon test. It can be
seen that for n = 56 the power is of 95%.
For 2D gamma evaluations, we observed that the both
confidence limits ULA and LLA for the absolute evaluation
were higher than the relative evaluation when varying the γ
criteria (as shown in Table 1). This is because the absolute
evaluation is more sensitive than the relative evaluation
Furthermore, by increasing the γ criteria from (3%, 3 mm) to
(5%, 5 mm) the p-value increased to reach a non-significant
difference, p > 0.05, between absolute and relative
evaluations with (5%, 5 mm). However, there was no
correlation between absolute dose and γ passing rates for
absolute evaluation.
Limit of gamma evaluation
Currently the most common γ criteria for IMRT is 3% for DD,
3 mm for DTA and the treatment per beam can be validated if
at least 95% of pixels have γ ≤ 1. The fundamental limitation
of the γ evaluation is that the measurements are performed
using a solid water phantom, in contrast to on the patient
who presents an heterogeneous medium. The evaluation is
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done for a unique rotation angle, equal to zero, for all fields.
We question the relevance of this method using a
homogenous phantom. It is troubling that using the
correlation test, the γ passing rates do not predict the clinical
impact resulting from the difference between calculated and
measured doses on the patient since the anatomic locations of
discrepancies are not displayed.
As can be seen from Figure 2 the large difference ranged from
8 to 10 cGy, presented in blue and red coloring. Therefore,
the Bland –Altham plot in Figure 4 shows that a larger
difference in dose of 10 to 15% was associated with low doses
ranging from 0.1 to 0.5 Gy.
It is interesting to note that the γ evaluation is not able to
predict the change in the dose volume histogram either for
the target volume or OAR.24-28 Chaikh et al., 2014, showed for
a specific patient, that 95% of pixels had γ < 1 with a γ average
value less than unity 24. In this case, we might conclude that
there is no difference between the reference plan and the
tested plan, but the real changes of dose distribution were not
taken into consideration to protect the OAR. It was observed
that a γ evaluation with (3%, 3 mm) under-estimated the dose
in a small fraction of the target volume and overestimated the
dose for OAR.24 Zhen et al. 2011, showed a significant
correlation between 3D dose volumes in a patient geometry
for QA comparison.25 In this study, the dose difference
reached up to 15%, while γ evaluation showed 95% of pixels
as having γ < 1. It may be that if the calculated dose in TPS
shows a plateau, it does not give the same form and may be in
the slope of the profile. The statistical analysis confirmed and
advocated that the limit of the γ evaluation should predict the
change that can be observed on clinical treatment planning.
The current QA method using a water phantom is not
sufficient to fully protect the patient. Therefore, γ evaluations
with (3%, 3 mm) or (4%, 4 mm) for minor deviations, are
inadequate, per se, to predict the risk to the OAR.
Recommendations
In our department, according to our study, the tolerance for
(4%, 4 mm) was validated only for minor deviations. It is also
interesting to quantify the degree of dose difference
according to the level of delivered dose. Much care should be
taken during interpretation, since sometimes a small
overestimation in dose can dramatically change the safety or
OAR. An example of this can be seen in Figure 2 where the
validation of the beam is obtained with a γ passing rate > 95%
using criteria (4%, 4 mm), however a small area with (a mild)
dose difference of 10 cGy represents (as much as) 10%
overestimation in dose in a relative evaluation. It is
interesting in this case to identify whether the 10% are
localized in the PTV or in the OAR.
FIG. 9: Flow chart of the dosimetry decisional method including successive steps to validate the IMRT plan per beam.
Figure 9 summarizes the recommendations and shows that
this method can be rapidly used to validate a treatment plan
beam by beam. The zones with pixels having γ > 1, should be
identified to verify if the overestimated dose is dispersed or
grouped in one same area and with a high or low level of dose.
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As a whole, we recommend the following steps to validate a
treatment plan beam by beam for IMRT:
• Case 1: The treatment is validated if the γ passing
rate is at least 97% of pixels having γ < 1 with (3%,
3 mm) criteria.
• Case 2: The treatment could be validated with
caution if the γ passing rate is at least 95% of pixels
having γ < 1 with (3%, 3 mm) criteria. However,
the pixel distribution should be checked to
determine whether the 5% of pixels having γ >1 is
dispersed or grouped in the same area. If these
pixels are dispersed, then the treatment can be
validated.
• Case 3: Minor deviation if the γ passing rate is at
least 95% of pixels having γ < 1 with (4%, 4 mm).
The distribution of pixels should be checked as
recommended in case 2.
• Case 4:major deviation if the γ passing rate < 95% of
pixels having γ < 1 with (4%, 4 mm). The treatment
should be rejected and a discussion between the
medical physicists and oncologists should take
place.
Conclusion
In this study, we used statistical methods to evaluate the
correlation between absolute dose and gamma passing rates.
According to the strong correlation we propose gamma
criteria of (4%, 4 mm), if the (3%, 3 mm) criterion with 95%
passing rate is not verified. The statistical methods confirmed
the limitations of a global evaluation based on the γ index to
predict the change of clinical treatment planning for target
volumes or OAR. This method can be easily implemented and
allows the clinician and medical physicist to validate the
treatment planning based on a visual display of data on
tolerance limits and acceptability criteria.
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